One of the first things you'll hear after a lung cancer diagnosis is, "Let's start with genetic testing." At first it sounds confusing. It's cancer in the lung, so why look at genes? But once the results come back, you realize that even with the same lung cancer, one person may begin treatment with a single pill while another receives chemotherapy infusions. What decides that fork in the road is the presence or absence of specific mutations like EGFR or ALK. If you have one of these mutations, you can use a drug that targets just that spot — a targeted therapy.
EGFR is a mutation found relatively often in non-small cell lung cancer, especially among Asians, non-smokers, and women. This mutation acts like a switch that keeps cancer cells growing, and the targeted drug works by pressing that switch and shutting it off — that's the easiest way to picture it. ALK is rarer, but when it's found there's a dedicated drug for it too. What both have in common is that they act quickly and tend to be more tolerable than chemo infusions. You can be spared a good deal of the hair loss and nausea, so many people starting these drugs for the first time recover their energy so well they wonder, "Is it really okay to feel this good?"
The problem starts here. These drugs don't work forever. At most a few years, at the shortest around a year, there comes a moment when the drug gradually stops working. The cancer quietly finds a way to slip past a drug that had been working well — this is called drug resistance. Cancer cells may create yet another mutation to dodge the drug, or simply detour through a different pathway to keep growing. A classic example with EGFR drugs is the appearance of another mutation called T790M, which makes the drug ineffective. So when a drug starts to fail, doctors do another tissue biopsy or blood test to check "how the cancer escaped this time."
The reassuring part is that resistance doesn't mean the road ends there. When resistance develops to a first-generation drug, there's a next-generation drug that can catch that resistance mutation too, and these days doctors sometimes start with a more powerful drug from the very beginning. On the ALK side, too, drugs have been developed across several generations, so when one is blocked you simply play the next card and treatment continues. In fact, this is exactly where lung cancer treatment differs most from the past. One drug being blocked is no longer the end — it's become possible to track the mutations and switch drugs in a long-term battle.
As all this unfolds, patients and families always have one worry tucked away in a corner of their minds: "How long will the drug I'm taking now keep working?" But there's no need to cling to that anxiety alone. Keep up with regular imaging to track the drug's response, and let your medical team know right away if your cough gets worse again or you start feeling short of breath — just staying on top of that rhythm lets you move quickly to the next step when resistance comes. Not skipping your dosing times matters more than you'd think, and if you're taking other supplements or medications, it's best to discuss it first. Surprisingly common stomach medicines or health supplements can interfere with how well a targeted drug is absorbed.
What's written here is only a broad-strokes explanation to help you understand targeted therapy and resistance. Your specific mutation type, drug choice, and the timing of tests all differ from person to person, so be sure to discuss your own situation directly with your treating physician.